Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.
Title Head of Information Technology
Reports to: CFO
Location Emeryville, CA (Hybrid) preferred or Remote with west coast hours
The Head of Information Technology leads the company’s technology strategy as it transitions from a development-stage biotech to a fully integrated commercial organization. Reporting to the CFO, this role is responsible for enterprise applications, cybersecurity, infrastructure, validation, data governance, IT operations, and digital enablement.
The Head of IT will build scalable, secure, and compliant technology capabilities that enable commercialization, regulatory readiness, and operational excellence. This leader partners closely with Commercial, Medical Affairs, Manufacturing & Supply, Quality, Regulatory, Clinical Development, Finance, HR, and Legal to align technology investments with business priorities.
This role also builds and leads a high-performing IT organization and manages key technology vendors and strategic partnerships.
Enterprise Technology Strategy & Leadership
Commercialization & Business Systems Enablement
Enterprise Applications & Integration
Cybersecurity, Risk & Compliance
Validation & GxP Systems
IT Operations & Infrastructure
Talent & Organizational Leadership
Vendor & Financial Management
The national salary range for this position is $290K to $ $325K USD annually.
The San Francisco Bay area salary range for this position is $310K to $ $340K USD annually.
The salary range is an estimate of what we reasonably expect to pay for this position, and the actual salary may vary based on various factors, including without limitation individual education, experience, tenure, skills and abilities, as well as internal equity and alignment with market data. This position is also eligible for bonus, benefits, and participation in Company’s stock plan.

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.